Biopharmaceuticals, including proteins, DNA and vaccines, are one of the fastest growing segments of the overall pharmaceutical market. While the hypodermic injection, the most common delivery method for these molecules, is effective, it also has limitations, including low patient compliance, need for medically trained personnel and biohazardous sharps after delivery. The overall goal of this thesis was to develop a new delivery system for biopharmaceuticals, based on dissolving polymer microneedles, which is effective and more patient compliant than the hypodermic needle. Microneedles are microscopic needles that are large enough to insert into the skin to deliver drugs effectively, while being short enough to avoid the pain causing nerves deep in the skin. An additional benefit of polymer microneedles is that the needles completely dissolve in the skin, leaving behind no biohazardous sharps. There are significant material and fabrication issues that must be overcome in the development of this new device. The first part of this thesis focused on the development of a new fabrication process, based on in situ photopolymerization, for the creation of polymer microneedles. These microneedles were shown to successfully insert into the skin, dissolving within a minute to deliver the encapsulated cargo, and retain full activity of encapsulated proteins. Next, we applied the microneedle technology to the delivery of the influenza virus. We found that the reformulation process required to encapsulate the influenza virus in polymer microneedles did not affect the antigenicity or immunogenicity of the virus. In addition, we used coated metal microneedles to successfully immunize mice with the influenza virus, verifying the delivery capabilities of a microneedle system. Finally, we used the dissolving polymer microneedles to successfully immunize mice with the influenza virus, resulting in full protection against lethal challenge after one immunization. This immune response was equivalent to the control intramuscular injection. In conclusion, we have developed dissolving polymer microneedles as an effective and patient compliant delivery system for biopharmaceuticals. This system could be especially applicable to mass immunization efforts or home use, since it can be self-administered and allows for easy disposal with no biohazardous sharps.

La vaccination du tissu cutané présente un fort potentiel, car elle permet le ciblage de l’antigène aux populations de cellules dendritiques uniques et spécialisées de la peau, et le recrutement de cellules inflammatoires du sang.Les cellules T helper folliculaires (TFH) jouent un rôle crucial dans l’établissement de la réponse humorale. Cependant, les interactions cellulaires et moléculaires qui gouvernent leur induction dans un contexte de vaccination restent à élucider.Mon projet de thèse a eu pour but de mieux comprendre les mécanismes d’induction des réponses TFH et humorales, par l’étude des événements précoces ayant lieu aux sites d’immunisation et d’induction de l’immunité adaptative après vaccination cutanée. L’utilisation de modèles murins nous a permis d’évaluer la contribution de différentes populations de la peau, du ganglion, et du sang dans la mise en place de ces réponses après immunisation intradermique avec un antigène particulaire présentant l’antigène modèle p24 du VIH. Cette étude a révélé un rôle crucial des cellules de Langerhans et des cellules dendritiques migratoires de la peau dans l’induction de réponses TFH et humorales.Nous avons ensuite évalué la capacité de différentes formulations d’adjuvants à polariser la réponse TFH et humorale contre un antigène de l’enveloppe du VIH à fort potentiel vaccinal. L’utilisation de l’émulsion IFA favorise l’induction des cellules TFH et induit la production d’anticorps neutralisants des souches du VIH.Ces résultats soulignent l’importance de cibler les DCs de la peau par l’utilisation de voies de vaccination pertinentes et l’utilisation d’adjuvants capables de favoriser la réponse cellulaire TFH. / Skin vaccination is of great interest, as it enables targeting of the antigen to unique and specialized dendritic cell populations of the skin, as well as recruitment of inflammatory blood cells.T follicular helper (TFH) cells play a critical role in the setting of the humoral response. However, the cellular and molecular interactions that underlie their induction after vaccination remain unknown.My thesis project aimed at understanding the immune mechanisms by which skin vaccination could favor the induction of TFH and humoral immune responses by studying the early events that take place in tissue and lymph node.Using mice models, we evaluated the relative contributions of various populations from the skin, lymph node and blood in the setting of TFH cell responses after intradermal immunization with nanoparticles coated with p24 antigen from HIV. This revealed a crucial role of Langerhans cells and skin migratory dendritic cells in the induction of TFH and germinal center responses.We then evaluated the ability of different adjuvant formulations to polarize the TFH and humoral response against a promising vaccine antigen from HIV envelope protein. Emulsifying the antigen in IFA favors the induction of TFH cells and induces the production of neutralizing antibodies able to block viral infection.This work highlights the relevance of targeting skin dendritic cells by using relevant vaccination routes and adjuvant formulation able to induce TFH cell responses.